Markets
C3.AI meme
SpongeBob

The company with the world’s most enviable stock ticker isn’t cashing in on AI

When your ticker is “AI,” people expect you to be riding the wave better than anyone else — that hasn’t happened for C3.ai.

9/5/25 5:46AM

Executives in corporate America are bending over backwards to describe their products as “AI-powered" or "AI-driven,” desperate to join the hype train. Weirdly, the stock with the enviable “AI” ticker is going backwards.

C3.ai, a 16-year-old enterprise software firm that develops AI tools for businesses and government, has fallen 34% in the past month — hit first by a weak preliminary forecast in August, followed by actual quarterly results on Wednesday, which founder Tom Siebel described as “completely unacceptable."

For the quarter ended July 31, revenue fell 19% year-over-year to $70.3 million, missing forecasts by a mile — Wall Street was expecting somewhere north of $100 million, per Bloomberg. Losses, unsurprisingly, ballooned as well, with a net loss of nearly -$117 million.

Indeed, since its 2020 IPO, the company has remained in the red, with losses continuing to widen.

C3.ai has rebranded several times since its founding in 2009: first as C3, focusing on carbon-emissions tracking, then as C3 IoT in 2016 during the Internet of Things boom, and finally as C3.ai in 2019, pivoting to artificial intelligence. Shares popped after its IPO, but are now down ~90% from its peak, seriously missing the AI rally that’s defined the last two years.

Siebel blamed the weak quarter on the company’s disruptive sales overhaul, while also citing his own health issues. This week, the company appointed Stephen Ehikian as CEO, with Siebel staying on as executive chairman. Despite the miss, Siebel emphasized C3.ai has an “extraordinarily large market opportunity, a superlative product offering, and exceptional levels of customer satisfaction.”

Still, analysts remain skeptical. Oppenheimer’s Timothy Horan warned the guidance may need to be reset lower, while Wedbush’s Dan Ives called the last quarter “brutal” and cautioned of “darker days” if performance doesn’t improve. 

Of course, AI isn’t a magic word that turns hype into profit. Although the frenzy around the tech has produced big winners, with Nvidia surpassing $4 trillion in market cap and Palantir transforming into a corporate behemoth thanks to a strong retail following, other names like Marvell, Adobe, and Salesforce are facing setbacks as their AI push has yet to meaningfully boost their bottom lines.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.